Results 171 to 180 of about 315,779 (268)

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

Annals of Neurology, EarlyView.
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell, Sebastian Hedberg, Fredrik Piehl   +2 more
wiley   +1 more source

Costs of Academic Engagement in Organized Plastic and Reconstructive Surgery in the United States. [PDF]

Arch Plast Surg
Shah KS, Prvulovic ST, Song DH.
europepmc   +1 more source

Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single‐Arm Clinical Trial

Annals of Neurology, EarlyView.
Objective To evaluate the effectiveness and safety of ocrelizumab in self‐identified black and Hispanic people with relapsing multiple sclerosis. Methods The Characterization of Ocrelizumab in Minorities with Multiple Sclerosis (CHIMES) trial, a prospective, open‐label, single‐arm, phase 4 study, intentionally recruited underrepresented populations in ...
Lilyana Amezcua, Anthony T. Reder, Evanthia Bernitsas, Nancy L. Monson, Timothy Vartanian, Gregory F. Wu, Mansoor Saleh, Annette Okai, Ahmed Z. Obeidat, Dilraj Sokhi, Rikisha Parekh, Jinglan Pei, Christopher Harp, David Clayton, Ibraheem Abioye, Mitzi J. Williams, for the CHIMES Study Group   +16 more
wiley   +1 more source

Predicting immune-related thyroiditis using polygenic risk scores in patients with advanced melanoma. [PDF]

J Immunother Cancer
Tarhini AA, Khaksar MA, Chen Z, Lee SJ, Stephen Hodi F, Li T, Yoder SJ, Streicher H, Sondak VK, Kirkwood JM, Wang X, Kanetsky PA.   +11 more
europepmc   +1 more source

Blood SOD1 Activity in ALS Patients Receiving Tofersen Treatment

Annals of Neurology, EarlyView.
Objective The antisense oligonucleotide tofersen is the first disease‐modifying drug for SOD1‐related amyotrophic lateral sclerosis (ALS) and was approved because of its ability to reduce SOD1 protein and neurofilament levels. The effect of tofersen on SOD1 activity is unclear but of clinical relevance because homozygous SOD1 mutations, linked to ...
Katharina Goehring, Enya Abler, Jakub Vavra, Kristina Mayer, Johannes Dorst, Zeynep Elmas, Maximilian Wiesenfarth, Lars Richter, Susanne Petri, Martin Regensburger, Peter Reilich, Bogdan Bjelica, Rea Lumi, Patrick Süß, Hayrettin Tumani, Markus Otto, Jochen H. Weishaupt, Albert C. Ludolph, Patrick Oeckl   +18 more
wiley   +1 more source

Impact of day-surgery on cancer treatment costs: a city-level case study in Ningxia, China. [PDF]

BMC Health Serv Res
Guo Y, Xing R, Maitland E, Nicholas S, Liu R, Xu C.   +5 more
europepmc   +1 more source

Discovery of an Antiviral Electron Transfer Process to Create Catalytically Self‐Sufficient Viral Restriction Factors

Angewandte Chemie International Edition, EarlyView.
CYB5R3 is identified as a putative electron‐transfer partner of viperin (RSAD2), explaining why ER localisation is required for antiviral activity. Its utilisation enabled the engineering of immune‐silent, catalytically self‐sufficient antiviral restriction factor enzymes (iCAREs) that produce an antiviral nucleoside triphosphate analogue (ANTA ...
Mengdi Wu, Nghi Thao Hoang, Deborah Grifagni, Meritxell Wu‐Lu, Yujie Sheng, Theo Situmorang, Pei‐Hsin Tai, Zheng Chen, Astrid Maluta, Mohammed Hakil, Bianca Susini, Hannah Florance, Peter‐Leon Hagedoorn, John Mark Sutton, Maria‐Andrea Mroginski, Simone Ciofi‐Baffoni, Kourosh H. Ebrahimi   +16 more
wiley   +1 more source

Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial. [PDF]

ESMO Open
Blaye C, Bidard FC, Hue L, Howarth K, Pierga JY, Dalenc F, Jacot W, Djerroudi L, Potonnier W, Dumas V, Lalet C, Maréchal M, Pulido M, Brunet M, Salabert L, Venat L, Maran-Gonzalez A, Saal LH, Franchet C, Birkeälv S, MacGrogan G, Bonnefoi H.   +21 more
europepmc   +1 more source

Molecular methods for differentiating Phragmites australis subspecies and identification of hybrid stands in the Upper Midwestern United States

Applications in Plant Sciences, EarlyView.
Abstract Premise In North America, Phragmites australis (common reed) has drawn a great deal of research attention. Non‐native P. australis subsp. australis is a noxious weed that has locally displaced native P. australis subsp. americanus in some areas.
Nicholas P. Tippery, Daniel J. Larkin, Julia Bohnen, Douglas L. Wendell, Neil O. Anderson, Susan M. Galatowitsch, Marie Abbey, Alan G. Smith, Andrzej K. Noyszewski   +8 more
wiley   +1 more source

Correction to: DEGRO statement on the KEYNOTE-689 trial: Perioperative immunotherapy in combination with adjuvant (chemo-)radiotherapy for resectable locally advanced head and neck cancers. [PDF]

Strahlenther Onkol
Schnellhardt S, Böke S, Tribius S, Krause M, Haderlein M, Rühle A, Süß C, Linge A, Hecht M, Balermpas P, Head and Neck Cancer Expert Panel of the German Society of Radiation Oncology DEGRO.   +10 more
europepmc   +1 more source